Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ809811-0,55
KB0,00
PKN64,0664,160,34
Msft-0,04
Nokia4,674,7495-0,30
IBM-0,26
Mercedes-Benz Group AG62,3662,38-0,21
PFE0,74
25.11.2022 23:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 25.11.2022 20:20:00
Nektar Therap (NKTR.O, NASDAQ Cons)
Závěr k 23.11.2022 Změna (%) Změna (USD) Objem obchodů (ks)
3,28 -1,22 -0,04 355 135
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.11.2022
Popis společnosti
Obecné informace
Název společnostiNektar Therapeutics
TickerNKTR
Kmenové akcie:Ordinary Shares
RICNKTR.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 31.12.2021 740
Akcie v oběhu k 27.10.2022 187 954 482
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice455 Mission Bay Blvd S
MěstoSAN FRANCISCO
PSČ94158-2158
ZeměUnited States
Kontatní osobaVivian Wu
Funkce kontaktní osobyAssociate Director, Investor Relations and Corporate Affairs
Telefon14 154 825 300
Fax13026555049
Kontatní telefon16 288 950 661

Business Summary: Nektar Therapeutics is a research-based biopharmaceutical company, which is focused on discovering and developing medicines in areas of unmet medical need. The Company's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Financial Summary: BRIEF: For the nine months ended 30 September 2022, Nektar Therapeutics revenues decreased 9% to $70M. Net loss decreased 18% to $308.5M. Revenues reflect Non-cash royalty revenue related to the decrease of 11% to $52.2M, Product sales decrease of 10% to $16M. Lower net loss reflects Research and development - Balancing val decrease of 38% to $161.4M (expense), Change in fair value of development deri increase from $7.6M (expense) to $33.4M (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 26.11.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorHoward Robin6914.02.200715.01.2007
Chief Financial Officer, Senior Vice PresidentJillian Thomsen5601.07.2022
Senior Vice President, General CounselMark Wilson50
Senior Vice President of Human Resources and FacilitiesRobert Bacci-
Senior Vice President - ManufacturingKevin Brodbeck-01.01.2002
Senior Vice President, Chief Medical OfficerBrian Kotzin-05.01.2021
Senior Vice President - Strategy and Corporate AffairsJennifer Ruddock-01.01.2019
Senior Vice President, Executive Clinical FellowMary Tagliaferri-
Chief Research and Development OfficerJonathan Zalevsky4701.10.201901.10.2019